0.11
+0.005(+5.00%)
Currency In CAD
Address
4820 Richard Road SW
Calgary, AB T3E 6L1
Canada
Phone
14032549252
Website
Sector
Healthcare
Industry
Biotechnology
Employees
19
First IPO Date
May 07, 2004
| Name | Title | Pay | Year Born |
| Mr. Donald J. McCaffrey | Co-Founder, Chairman, President, Chief Executive Officer & Secretary | 505,200 | N/A |
| Mr. Aaron Bradley Cann C.A., CPA, CBV | Chief Financial Officer | 211,350 | N/A |
| Dr. Ewelina Kulikowski Ph.D. | Chief Scientific Officer | 250,000 | N/A |
| Dr. Michael Sweeney M.D. | Senior Vice President of Clinical Development | 530,680 | 1961 |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.